- Home
- LCTX vs FRGE Comparison
LCTX vs FRGE Comparison
Compare LCTX & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- FRGE
- Stock Information
- Founded
- LCTX 1990
- FRGE 2014
- Country
- LCTX United States
- FRGE United States
- Employees
- LCTX N/A
- FRGE N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- FRGE Computer Software: Prepackaged Software
- Sector
- LCTX Health Care
- FRGE Technology
- Exchange
- LCTX Nasdaq
- FRGE Nasdaq
- Market Cap
- LCTX 274.0M
- FRGE 262.8M
- IPO Year
- LCTX N/A
- FRGE N/A
- Fundamental
- Price
- LCTX $1.73
- FRGE $20.67
- Analyst Decision
- LCTX Strong Buy
- FRGE Buy
- Analyst Count
- LCTX 4
- FRGE 5
- Target Price
- LCTX $4.25
- FRGE $35.50
- AVG Volume (30 Days)
- LCTX 1.8M
- FRGE 81.5K
- Earning Date
- LCTX 11-13-2025
- FRGE 11-04-2025
- Dividend Yield
- LCTX N/A
- FRGE N/A
- EPS Growth
- LCTX N/A
- FRGE N/A
- EPS
- LCTX N/A
- FRGE N/A
- Revenue
- LCTX $10,914,000.00
- FRGE $90,840,000.00
- Revenue This Year
- LCTX N/A
- FRGE $32.73
- Revenue Next Year
- LCTX $176.00
- FRGE $21.74
- P/E Ratio
- LCTX N/A
- FRGE N/A
- Revenue Growth
- LCTX 76.43
- FRGE 14.78
- 52 Week Low
- LCTX $0.37
- FRGE $6.60
- 52 Week High
- LCTX $1.85
- FRGE $24.90
- Technical
- Relative Strength Index (RSI)
- LCTX 62.37
- FRGE 66.25
- Support Level
- LCTX $1.53
- FRGE $16.16
- Resistance Level
- LCTX $1.77
- FRGE $18.98
- Average True Range (ATR)
- LCTX 0.10
- FRGE 1.03
- MACD
- LCTX -0.01
- FRGE 0.32
- Stochastic Oscillator
- LCTX 74.94
- FRGE 100.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.